NMRA — Neumora Therapeutics Balance Sheet
0.000.00%
- $344.42m
- $192.46m
- 10
- 15
- 89
- 31
Annual balance sheet for Neumora Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 192 | 409 | 372 | 454 | 308 |
| Net Total Receivables | 0.148 | 0.2 | 0.919 | 0.939 | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 194 | 416 | 388 | 478 | 314 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.92 | 4.04 | 10.6 | 6.86 | 2.92 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 198 | 429 | 426 | 496 | 317 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 9.37 | 23.3 | 23.7 | 25.1 | 29.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.7 | 24.7 | 29.4 | 27.1 | 29.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 187 | 405 | 397 | 469 | 287 |
| Total Liabilities & Shareholders' Equity | 198 | 429 | 426 | 496 | 317 |
| Total Common Shares Outstanding |